News
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
51mon MSNOpinion
Voices: Yes, Mounjaro is set to treble in price – but don’t abandon weight-loss jabs until you read this
COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...
Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...
Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
What started as a medical solution to diabetes has exploded into a worldwide weight-loss trend, with demand skyrocketing as ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...
20h
Zacks.com on MSNIs Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...
A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results